重组GFP-VEGF6a融合肽的构建表达及其抗肿瘤活性

孟雨菡; 刘素丽; 张会勇; 曹荣月; 范晓旭; 范 豪; 刘景晶

重组GFP-VEGF6a融合肽的构建表达及其抗肿瘤活性

1.
中国药科大学生命科学与技术学院
2.
上海一就生物医药有限公司

基金项目: 国家自然科学基金资助项目(No.30772570,No.30872393)；国家基础科学人才培养基金资助项目(No.J0630858)

计量
- 文章访问数: 1770
- HTML全文浏览量: 0
- PDF下载量: 2188
出版历程
- 刊出日期: 2011-02-24

Construction,expression and activity studies of recombinant GFP-VEGF6a fusion polypeptide

摘要

摘要: 为了探讨血管内皮生长因子6a（VEGF6a）的抗肿瘤及其抑制外周血管生成活性，采用两次加端PCR技术，将VEGF6a片段的基因和绿色荧光蛋白（GFP）基因通过GGGS柔性片段融合，连接至pET28a载体，构建GFP-VEGF6a(GFP6a)融合肽E.coli表达菌。GFP6a融合肽通过乳糖诱导表达和肝素亲和树脂精制得到。建立皮内和皮下移植型肝癌ICR小鼠模型，验证了VEGF6a抑制肿瘤外周血管及抗肿瘤活性。结果表明，与阴性对照GFP比较，GFP6a 200 mg/kg组和20 mg/kg组均明显抑制肿瘤外周血管生成，抑制H22肝癌细胞体内生长，瘤重抑制率分别为70.9%和56.1%(P<0.01)。本研究显示，VEGF6a具有潜在的抗肿瘤活性。
- GFP-VEGF6a融合肽 /
- H22细胞 /
- 肝癌 /
- 抑制血管生成
Abstract: To investigate the antitumor and anti-angiogenesis effects of vascular endothelial growth factor 6a (VEGF6a),VEGF6a and green fluorescent protein (GFP) gene were linked by GGGS segment and cloned into pET28a vector by PCR.GFP-VEGF6a (GFP6a) fusion polypeptides were expressed in E.coli and purified by heparin sepharose chromatograph.ICR mice bearing H22 hepatoma carcinoma cells was treated with subcutaneous injection of GFP6a and GFP.Compared with the negative control GFP,GFP6a (200mg/kg,20 mg/kg) significantly inhibited the growth of the peripheral blood vessels and H22 cells in vivo,with the inhibition ratios of 70.9% and 56.1% (P<0.01),respectively.VEGF6a has the potency in the application of anticancer clinical therapy.
- GFP-VEGF6a fusion polypeptide /
- H22 cell /
- hepatoma /
- angiogenesis inhibition

HTML全文

参考文献(0)

施引文献

资源附件(0)

计量

文章访问数: 1770
HTML全文浏览量: 0
PDF下载量: 2188
被引次数: 0

重组GFP-VEGF6a融合肽的构建表达及其抗肿瘤活性

计量

出版历程

Construction,expression and activity studies of recombinant GFP-VEGF6a fusion polypeptide

计量

出版历程

目录